BiotechTube
CytoImmune Therapeutics

CytoImmune Therapeutics

San Diego, United States· Est.
cytoimmune.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $37M

Overview

CytoImmune Therapeutics is a private, clinical-stage biotech focused on developing off-the-shelf CAR-NK cell therapies for cancer. The company's core strength lies in its proprietary NK cell engineering platform, built upon decades of foundational research from its scientific founders, Drs. Caligiuri and Yu. With a seasoned leadership team experienced in cell therapy CMC and commercialization, and an in-house manufacturing capability, CytoImmune is positioned to advance allogeneic NK cell therapies through clinical development. Its strategy targets the significant limitations of current autologous CAR-T treatments, such as manufacturing complexity and patient accessibility.

Oncology

Technology Platform

Proprietary NK cell engineering and expansion platform for creating allogeneic, off-the-shelf CAR-NK cell therapies.

Funding History

2
Total raised:$37M
Series A$32M
Seed$5M

Opportunities

The primary opportunity lies in addressing the major limitations of current autologous CAR-T therapies by providing an effective, readily available, and potentially safer off-the-shelf alternative.
Success in solid tumors, a vastly larger market than hematologic cancers, represents a transformative commercial opportunity.

Risk Factors

Key risks include clinical failure of the novel CAR-NK approach, particularly in solid tumors; intense competition from other allogeneic cell therapy developers; and the significant financial risk associated with funding expensive clinical trials and scaling manufacturing as a pre-revenue company.

Competitive Landscape

CytoImmune competes in the rapidly evolving allogeneic cell therapy space against companies like Fate Therapeutics, Nkarta, Caribou Biosciences, and Allogene Therapeutics, as well as large pharma partners. Differentiation relies on its specific NK cell engineering platform, manufacturing expertise, and foundational science.

More companies in Cell & Gene Therapy →More companies in United States →